Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
$ADAP will sell TECELRA, lete-cel, afami-cel, and uza-cel to US WorldMeds for $55M upfront and up to $30M in milestones. US WorldMeds will handle commercialization and development, while Adaptimmune focuses on preclinical programs (PRAME, CD70, allogeneic) and will restructure. https://t.co/zfAdKXvUDE
$ADAP - Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds - https://t.co/pXnqCnsWtn
Adaptimmune sells 4 cell therapies to pharma for $55M, plans layoffs https://t.co/6IHKlTPwiz #biotech #news
Adaptimmune has entered into a definitive agreement to sell four of its cell therapy assets—TECELRA, lete-cel, afami-cel, and uza-cel—to US WorldMeds. The deal includes an upfront payment of $55 million, with the potential for an additional $30 million in milestone payments. Following the sale, US WorldMeds will assume responsibility for the commercialization and development of these therapies. Adaptimmune plans to refocus its efforts on preclinical programs, including PRAME, CD70, and allogeneic therapies, and will undertake a restructuring that includes layoffs.
